Literature DB >> 18303046

L- and S-endoglin differentially modulate TGFbeta1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts.

Soraya Velasco1, Patricia Alvarez-Muñoz, Miguel Pericacho, Peter Ten Dijke, Carmelo Bernabéu, José M López-Novoa, Alicia Rodríguez-Barbero.   

Abstract

TGFbeta regulates cellular processes by binding to type I and type II TGFbeta receptors (TbetaRI and TbetaRII, respectively). In addition to these signaling receptors, endoglin is an accessory TGFbeta receptor that regulates TGFbeta signaling. Although there are two different alternatively spliced isoforms of endoglin, L-endoglin (L, long) and S-endoglin (S, short), little is known about the effects of S-endoglin isoform on TGFbeta signaling. Here, we have analyzed the TGFbeta1 signaling pathways and the effects of L- and S-endoglin in endoglin-deficient L6E9 cells. We found that TGFbeta activates two distinct TbetaRI-Smad signaling pathways: ALK1-Smad1-Id1 and ALK5-Smad2-PAI1, in these cells. Interestingly, L-endoglin enhanced the ALK1-Id1 pathway, while S-endoglin promoted the ALK5-PAI1 route. These effects on signaling are supported by biological effects on TGFbeta1-induced collagen I expression and inhibition of cell proliferation. Thus, while L-endoglin decreased TGFbeta1-induced collagen I and CTGF expression and increased TGFbeta1-induced proliferation, S-endoglin strongly increased TGFbeta1-induced collagen I and CTGF expression, and reduced TGFbeta1-induced cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18303046     DOI: 10.1242/jcs.023283

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  44 in total

1.  Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure.

Authors:  Navin K Kapur; Szuhuei Wilson; Adil A Yunis; Xiaoying Qiao; Emily Mackey; Vikram Paruchuri; Corey Baker; Mark J Aronovitz; S Ananth Karumanchi; Michelle Letarte; David A Kass; Michael E Mendelsohn; Richard H Karas
Journal:  Circulation       Date:  2012-05-16       Impact factor: 29.690

Review 2.  Endoglin-targeted cancer therapy.

Authors:  Ben K Seon; Akinao Haba; Fumihiko Matsuno; Norihiko Takahashi; Masanori Tsujie; Xinwei She; Naoko Harada; Shima Uneda; Tomoko Tsujie; Hirofumi Toi; Hilda Tsai; Yuro Haruta
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

3.  Control of RNA processing by a large non-coding RNA over-expressed in carcinomas.

Authors:  Rui Lin; Manami Roychowdhury-Saha; Chris Black; Andrew T Watt; Eric G Marcusson; Susan M Freier; Thomas S Edgington
Journal:  FEBS Lett       Date:  2011-01-23       Impact factor: 4.124

Review 4.  Specificity, versatility, and control of TGF-β family signaling.

Authors:  Rik Derynck; Erine H Budi
Journal:  Sci Signal       Date:  2019-02-26       Impact factor: 8.192

Review 5.  Signaling Receptors for TGF-β Family Members.

Authors:  Carl-Henrik Heldin; Aristidis Moustakas
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-08-01       Impact factor: 10.005

6.  Endoglin promotes TGF-β/Smad1 signaling in scleroderma fibroblasts.

Authors:  Erin Morris; Izabela Chrobak; Andreea Bujor; Faye Hant; Christine Mummery; Peter Ten Dijke; Maria Trojanowska
Journal:  J Cell Physiol       Date:  2011-12       Impact factor: 6.384

7.  Impact of selective anti-BMP9 treatment on tumor cells and tumor angiogenesis.

Authors: 
Journal:  Mol Oncol       Date:  2016-12       Impact factor: 6.603

Review 8.  Role of endoglin in fibrosis and scleroderma.

Authors:  Janita A Maring; Maria Trojanowska; Peter ten Dijke
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

9.  Characterization of the human Activin-A receptor type II-like kinase 1 (ACVRL1) promoter and its regulation by Sp1.

Authors:  Eva M Garrido-Martin; Francisco J Blanco; Africa Fernandez-L; Carmen Langa; Calvin P Vary; Ursula E Lee; Scott L Friedman; Luisa M Botella; Carmelo Bernabeu
Journal:  BMC Mol Biol       Date:  2010-06-29       Impact factor: 2.946

10.  Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature.

Authors:  Shima Uneda; Hirofumi Toi; Tomoko Tsujie; Masanori Tsujie; Naoko Harada; Hilda Tsai; Ben K Seon
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.